WO2003103475A2 - Prevention and reduction of blood loss - Google Patents
Prevention and reduction of blood loss Download PDFInfo
- Publication number
- WO2003103475A2 WO2003103475A2 PCT/US2003/017665 US0317665W WO03103475A2 WO 2003103475 A2 WO2003103475 A2 WO 2003103475A2 US 0317665 W US0317665 W US 0317665W WO 03103475 A2 WO03103475 A2 WO 03103475A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phe
- amino acid
- gly
- ala
- cys
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE60333758T DE60333758D1 (en) | 2002-06-07 | 2003-06-06 | Prevention and reduction of ischemia |
EP03757339A EP1531791B1 (en) | 2002-06-07 | 2003-06-06 | Prevention and reduction of ischemia |
AT03757339T ATE477020T1 (en) | 2002-06-07 | 2003-06-06 | PREVENTION AND REDUCTION OF ISCHEMIA |
DK03757339.1T DK1531791T3 (en) | 2002-06-07 | 2003-06-06 | Prevention and restriction of ischemia |
JP2004510605A JP2005534647A (en) | 2002-06-07 | 2003-06-06 | Prevention and reduction of blood loss |
AU2003243394A AU2003243394B2 (en) | 2002-06-07 | 2003-06-06 | Prevention and reduction of blood loss |
CA2488558A CA2488558C (en) | 2002-06-07 | 2003-06-06 | Prevention and reduction of blood loss |
HK05109179.9A HK1077181A1 (en) | 2003-06-06 | 2005-10-18 | Prevention and reduction of ischemia |
AU2008202377A AU2008202377B2 (en) | 2002-06-07 | 2008-05-29 | Prevention and reduction of blood loss |
AU2011201811A AU2011201811A1 (en) | 2002-06-07 | 2011-04-20 | Prevention and reduction of blood loss |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38723902P | 2002-06-07 | 2002-06-07 | |
US60/387,239 | 2002-06-07 | ||
US40700302P | 2002-08-28 | 2002-08-28 | |
US60/407,003 | 2002-08-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003103475A2 true WO2003103475A2 (en) | 2003-12-18 |
WO2003103475A3 WO2003103475A3 (en) | 2005-03-10 |
Family
ID=29739936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/017665 WO2003103475A2 (en) | 2002-06-07 | 2003-06-06 | Prevention and reduction of blood loss |
Country Status (13)
Country | Link |
---|---|
US (13) | US7064107B2 (en) |
EP (4) | EP2311432B1 (en) |
JP (3) | JP2005534647A (en) |
AT (2) | ATE477020T1 (en) |
AU (3) | AU2003243394B2 (en) |
CA (1) | CA2488558C (en) |
CY (1) | CY1112228T1 (en) |
DE (1) | DE60333758D1 (en) |
DK (4) | DK1941867T3 (en) |
ES (4) | ES2559927T3 (en) |
HK (3) | HK1119955A1 (en) |
PT (4) | PT2311432E (en) |
WO (1) | WO2003103475A2 (en) |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1542710A1 (en) * | 2002-08-28 | 2005-06-22 | Dyax Corp. | Methods for preserving organs and tissues |
US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
US7811991B2 (en) | 2002-06-07 | 2010-10-12 | Dyax Corp. | Prevention and reduction of blood loss |
WO2011085103A2 (en) | 2010-01-06 | 2011-07-14 | Dyax Corp. | Plasma kallikrein binding proteins |
WO2011089022A1 (en) | 2010-01-25 | 2011-07-28 | Ecp Entwicklungsgesellschaft Mbh | Fluid pump having a radially compressible rotor |
US8119137B2 (en) * | 2004-12-23 | 2012-02-21 | Csl Behring Gmbh | Prevention of thrombus formation and/or stabilization with inhibitors of factor XII or activated factor XII |
EP2374472A3 (en) * | 2006-03-16 | 2012-05-16 | Dyax Corp. | Compositions and methods for treating ophthalmic disorders |
US8637454B2 (en) | 2009-01-06 | 2014-01-28 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
US8663629B2 (en) | 1994-01-11 | 2014-03-04 | Dyax Corp. | Kallikrein-binding “kunitz domain” proteins and analogues thereof |
WO2014113712A1 (en) | 2013-01-20 | 2014-07-24 | Dyax Corp. | Evaluation and treatment of bradykinin-mediated disorders |
US8816055B2 (en) | 2011-01-06 | 2014-08-26 | Dyax Corp. | Plasma kallikrein binding proteins |
WO2015061182A1 (en) | 2013-10-21 | 2015-04-30 | Dyax Corp. | Diagnosis and treatment of autoimmune diseases |
WO2015112578A1 (en) | 2014-01-21 | 2015-07-30 | Dyax Corp. | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema |
US9107928B2 (en) | 2006-03-16 | 2015-08-18 | Dyax Corp. | Compositions and methods for treating ophthalmic disorders |
AU2012267546B2 (en) * | 2011-06-10 | 2015-12-24 | Ionis Pharmaceuticals, Inc. | Methods for modulating kallikrein (KLKB1) expression |
US9322021B2 (en) | 2011-06-29 | 2016-04-26 | Ionis Pharmaceuticals, Inc. | Methods for modulating kallikrein (KLKB1) expression |
US9670492B2 (en) | 2013-08-28 | 2017-06-06 | Ionis Pharmaceuticals, Inc. | Modulation of prekallikrein (PKK) expression |
WO2017100679A1 (en) | 2015-12-11 | 2017-06-15 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
EP3470837A1 (en) | 2013-01-20 | 2019-04-17 | Dyax Corp. | Treatment of pkal-mediated disorders |
US10294477B2 (en) | 2014-05-01 | 2019-05-21 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating PKK expression |
US10428158B2 (en) | 2014-03-27 | 2019-10-01 | Dyax Corp. | Compositions and methods for treatment of diabetic macular edema |
WO2020047352A1 (en) | 2018-08-30 | 2020-03-05 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
WO2020186132A1 (en) | 2019-03-14 | 2020-09-17 | Dyax Corp. | Treating hereditary angioedema attack with reduced dosage of antibodies binding to human plasma kallikrein |
EP3808857A1 (en) | 2013-10-21 | 2021-04-21 | Dyax Corp. | Assays for determining plasma kallikrein system biomarkers |
WO2021146160A1 (en) | 2020-01-13 | 2021-07-22 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack |
WO2021202948A2 (en) | 2020-04-04 | 2021-10-07 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for treating acute respiratory distress syndrome |
EP3916020A1 (en) | 2015-03-30 | 2021-12-01 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4137997B2 (en) | 1994-01-11 | 2008-08-20 | ダイアックス コープ. | Inhibitors of human plasmin derived from the Kunitz domain |
US6801634B2 (en) | 2000-07-31 | 2004-10-05 | Harman International Industries, Inc. | Loudspeaker coil suspension system |
US20050222023A1 (en) * | 2002-02-07 | 2005-10-06 | Hans-Peter Hauser | Albumin-fused kunitz domain peptides |
US6989369B2 (en) * | 2003-02-07 | 2006-01-24 | Dyax Corp. | Kunitz domain peptides |
JP4739207B2 (en) * | 2003-08-29 | 2011-08-03 | ダイアックス コーポレーション | PolyPEGylated protease inhibitors |
WO2005027834A2 (en) * | 2003-09-12 | 2005-03-31 | Z-Medica Corporation | Partially hydrated hemostatic agent |
US20060177971A1 (en) * | 2004-01-13 | 2006-08-10 | Jsr Corporation | Anisotropically conductive connector, production process thereof and application product thereof |
US20060178609A1 (en) | 2005-02-09 | 2006-08-10 | Z-Medica, Llc | Devices and methods for the delivery of molecular sieve materials for the formation of blood clots |
KR20070117589A (en) | 2005-02-15 | 2007-12-12 | 버지니아 커먼웰스 유니버시티 | Mineral technologies (mt) for acute hemostasis and for the treatment of acute wounds and chronic ulcers |
US9829494B2 (en) | 2005-12-01 | 2017-11-28 | Adrenomed Ag | Methods of treatment using ADM antibodies |
JP2009529542A (en) * | 2006-03-10 | 2009-08-20 | ダイアックス コーポレーション | Ecarantide formulation |
US8938898B2 (en) * | 2006-04-27 | 2015-01-27 | Z-Medica, Llc | Devices for the identification of medical products |
US7604819B2 (en) * | 2006-05-26 | 2009-10-20 | Z-Medica Corporation | Clay-based hemostatic agents and devices for the delivery thereof |
US7968114B2 (en) | 2006-05-26 | 2011-06-28 | Z-Medica Corporation | Clay-based hemostatic agents and devices for the delivery thereof |
US8202532B2 (en) | 2006-05-26 | 2012-06-19 | Z-Medica Corporation | Clay-based hemostatic agents and devices for the delivery thereof |
US20080085300A1 (en) * | 2006-10-06 | 2008-04-10 | Z-Medica Corporation | Hemostatic compositions and method of manufacture |
US9345457B2 (en) | 2006-12-13 | 2016-05-24 | Devicor Medical Products, Inc. | Presentation of biopsy sample by biopsy device |
EP2195010A4 (en) * | 2007-08-21 | 2012-03-14 | Genzyme Corp | Treatment with kallikrein inhibitors |
JP2010536883A (en) * | 2007-08-23 | 2010-12-02 | ジェンザイム・コーポレーション | Treatment with kallikrein inhibitors |
WO2009032884A1 (en) * | 2007-09-05 | 2009-03-12 | Z-Medica Corporation | Wound healing with zeolite-based hemostatic devices |
US8858969B2 (en) | 2010-09-22 | 2014-10-14 | Z-Medica, Llc | Hemostatic compositions, devices, and methods |
RS58880B1 (en) | 2011-11-16 | 2019-08-30 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition |
CA2856141C (en) | 2011-11-16 | 2019-06-04 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig scaffold for use in therapy |
AU2012338730B2 (en) | 2011-11-16 | 2017-07-06 | Adrenomed Ag | Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition |
HUE032648T2 (en) | 2011-11-16 | 2017-10-30 | Sphingotec Gmbh | Adrenomedullin assays and methods for determining mature adrenomedullin |
HUE042477T2 (en) | 2011-11-16 | 2019-07-29 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease |
US9402900B2 (en) | 2011-11-16 | 2016-08-02 | Adrenomed Ag | Methods of modulating adrenomedullin by administering an anti-adrenomedullin (ADM) antibody |
CN103308689B (en) | 2012-03-08 | 2017-04-12 | 思芬构技术有限公司 | A method for predicting the risk of getting cancer or diagnosing cancer in a female subject |
CN103308670B (en) | 2012-03-08 | 2017-06-09 | 思芬构技术有限公司 | For predicting the method that object suffers from the risk of diabetes and/or metabolic syndrome |
CN103308673B (en) | 2012-03-08 | 2017-05-31 | 思芬构技术有限公司 | For predicting in female subject the method for the risk of cardiovascular event |
CA3183404A1 (en) | 2012-06-22 | 2013-12-27 | Teleflex Life Sciences Limited | Hemostatic devices |
ES2810001T3 (en) | 2012-10-02 | 2021-03-08 | Sphingotec Gmbh | A method to diagnose or monitor kidney function |
RU2677895C2 (en) | 2013-01-08 | 2019-01-22 | Сфинготек Гмбх | Fasting levels of growth hormone as predictive marker of cardiovascular risk |
CN105102985B (en) | 2013-03-20 | 2018-05-18 | 斯弗因高泰克有限公司 | For blood pressure to be instructed to decline the adrenomedulin of therapy |
EP3002589A1 (en) | 2014-10-01 | 2016-04-06 | sphingotec GmbH | A method for stratifying a female subject for hormone replacement therapy |
SG11201708655UA (en) | 2015-04-24 | 2017-11-29 | Sphingotec Gmbh | A method for predicting the risk of incidence of chronic kidney disease |
DK3365685T3 (en) | 2015-10-19 | 2021-03-01 | Dyax Corp | IMMUNOASSAY FOR DETECTION OF COLUMNED HIGH MOLECULAR KININOGEN |
EP3854817A1 (en) | 2016-04-21 | 2021-07-28 | 4TEEN4 Pharmaceuticals GmbH | Methods for determining dpp3 and therapeutic methods |
MA45493A (en) | 2016-06-27 | 2019-05-01 | Aicuris Anti Infective Cures Gmbh | HCMC ENTRY INHIBITORS. |
JP7191813B2 (en) | 2016-07-08 | 2022-12-19 | シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | Adrenomedullin for Assessing Congestion in Subjects Suffering from Acute Heart Failure |
WO2018053260A1 (en) | 2016-09-16 | 2018-03-22 | Dyax Corp. | Rna biomarkers for hereditary angioedema |
MX2019002918A (en) | 2016-09-16 | 2019-07-18 | Dyax Corp | Metabolite biomarkers for diseases associated with the contact activation system. |
CA3037154A1 (en) | 2016-09-16 | 2018-03-22 | Dyax Corp. | Protein biomarkers for diseases associated with the contact activation system |
EP3309550A1 (en) | 2016-10-12 | 2018-04-18 | sphingotec GmbH | Method for the detection of apolipoprotein e4 |
BR112019011713A2 (en) | 2016-12-16 | 2019-10-15 | Adrenomed Ag | anti-adrenomedulin antibody (adm) or anti-adm antibody fragment or anti-adm framework not for use in the intervention and therapy of congestion in a patient in need thereof |
EP3339324A1 (en) | 2016-12-22 | 2018-06-27 | sphingotec GmbH | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof |
CA3065415A1 (en) | 2017-05-30 | 2018-12-06 | Sphingotec Gmbh | A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction |
CN111511390A (en) | 2017-09-25 | 2020-08-07 | 艾德里诺医药公司 | anti-Adrenomedullin (ADM) binding agents for the treatment or prevention of disease symptoms |
MX2020004072A (en) | 2017-10-18 | 2020-07-28 | Adrenomed Ag | Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder. |
MX2020004219A (en) | 2017-10-24 | 2020-07-22 | Sphingotec Gmbh | Selenoprotein p for prediction of a first cardiovascular event. |
SG11202002594PA (en) | 2017-10-25 | 2020-04-29 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 binder directed to and binding to specific dpp3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress |
EP3569614A1 (en) | 2018-05-18 | 2019-11-20 | Julius-Maximilians-Universität Würzburg | Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase |
EP3586865A1 (en) | 2018-06-21 | 2020-01-01 | Charité - Universitätsmedizin Berlin | Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis |
CN113631926A (en) | 2018-12-20 | 2021-11-09 | 思芬构技术有限公司 | Selenoprotein P in heart failure |
US20220211798A1 (en) | 2018-12-21 | 2022-07-07 | 4TEEN4 Pharmaceuticals GmbH | Therapy guidance and/or therapy monitoring for a treatment with angiotensin-receptor-agonist and/or a precursor thereof |
JP2022544942A (en) | 2019-08-15 | 2022-10-24 | シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | Methods of diagnosing or monitoring renal function or diagnosing renal dysfunction in pediatric patients |
RU2712629C1 (en) * | 2019-08-27 | 2020-01-30 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) | Method for prediction of cardiovascular complications in patients with ischemic heart disease in a combination with postinfarction left ventricular aneurysm |
AU2020338818A1 (en) | 2019-08-30 | 2022-03-31 | 4TEEN4 Pharmaceuticals GmbH | Therapy guidance and/or therapy monitoring for treatment of shock |
EP3871689A1 (en) | 2020-02-26 | 2021-09-01 | sphingotec GmbH | Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c |
BR112022015215A2 (en) | 2020-02-27 | 2022-10-11 | 4TEEN4 Pharmaceuticals GmbH | DPP3 FOR GUIDANCE, MONITORING AND STRATIFICATION OF NT-ADM ANTIBODY THERAPY IN PATIENTS WITH SHOCK |
WO2021170880A2 (en) | 2020-02-27 | 2021-09-02 | Adrenomed Ag | Anti-adrenomedullin (adm) binder for use in therapy of patients in shock |
US20230104578A1 (en) | 2020-02-27 | 2023-04-06 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
EP3922993A1 (en) | 2020-06-12 | 2021-12-15 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 in patients infected with coronavirus |
EP4121771A1 (en) | 2020-03-16 | 2023-01-25 | AdrenoMed AG | Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin |
JP2023518731A (en) | 2020-03-16 | 2023-05-08 | 4ティーン4 ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | DPP3 in patients infected with coronavirus |
EP4023218A1 (en) | 2020-12-02 | 2022-07-06 | S-Form Pharma | Combination therapy for patients having acute and/or persistent dyspnea |
EP4356139A1 (en) | 2021-06-18 | 2024-04-24 | sphingotec GmbH | A method for predicting sepsis and septic shock |
KR20240041912A (en) | 2021-06-29 | 2024-04-01 | 베리솔 게엠베하 | Multiple biomarkers for identifying selenium deficiency in body fluids |
WO2024003617A2 (en) | 2022-06-30 | 2024-01-04 | Takeda Pharmaceutical Company Limited | Protein biomarkers for lanadelumab treatment |
WO2024023369A1 (en) | 2022-07-29 | 2024-02-01 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
WO2024023368A1 (en) | 2022-07-29 | 2024-02-01 | 4TEEN4 Pharmaceuticals GmbH | Prediction of an increase of dpp3 in a patient with septic shock |
Family Cites Families (211)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT275583B (en) | 1964-03-04 | 1969-10-27 | Plasser Bahnbaumasch Franz | Profile-free machine for cleaning the railway bed ballast |
BR6915369D0 (en) | 1969-02-27 | 1973-03-13 | Bayer Ag | USE OF BIOLOGICAL PROTEASE INHIBITORS FOR THE CONSERVATION OF TISSUE AND FOOD ORGANS |
US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
DE2619246A1 (en) | 1976-04-30 | 1977-11-10 | Bayer Ag | DESAMINO DERIVATIVES OF KALLIKREIN TRYPSIN INHIBITOR, THE METHOD FOR THEIR PRODUCTION AND THEIR USE AS A MEDICINAL PRODUCT |
US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
DE2654124A1 (en) | 1976-11-29 | 1978-06-01 | Bayer Ag | DERIVATIVES OF TRYPSIN-KALLIKREIN-INHIBITOR FROM BOVINE ORGANS (BPTI) WITH PROTEASE-INHIBITING EFFECT AND ANTIPHLOGISTIC EFFECT, THEIR PRODUCTION AND USE AS A MEDICINAL PRODUCT |
US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
EP0003248A1 (en) * | 1977-11-09 | 1979-08-08 | Animark Products Limited | Composition and method for bleaching hair or keratinous fibre |
US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
AT359653B (en) | 1979-02-15 | 1980-11-25 | Immuno Ag | METHOD FOR PRODUCING A TISSUE ADHESIVE |
US4299537A (en) * | 1979-06-19 | 1981-11-10 | Evans Frederick C | Interlinked variable-pitch blades for windmills and turbines |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
AU560584B2 (en) | 1983-07-28 | 1987-04-09 | Bayer Aktiengesellschaft | Homologues of aprotinin |
US4657893A (en) | 1984-05-09 | 1987-04-14 | Syntex (U.S.A.) Inc. | 4H-3,1-benzoxazin-4-ones and related compounds and use as enzyme inhibitors |
US4845242A (en) | 1987-04-28 | 1989-07-04 | Georgia Tech Research Corporation | Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents |
US4609725A (en) | 1984-10-09 | 1986-09-02 | Merck & Co., Inc. | Cardiac atrial peptides |
US4931385A (en) | 1985-06-24 | 1990-06-05 | Hygeia Sciences, Incorporated | Enzyme immunoassays and immunologic reagents |
US5444156A (en) * | 1985-07-12 | 1995-08-22 | Temple University-Of The Commonwealth System Of Higher Education | Monoclonal antibodies to human plasma prekallikrein |
JPH0623113B2 (en) | 1986-01-31 | 1994-03-30 | 浩 前田 | Cancerous breast / ascites retention inhibitor |
EP0255011A3 (en) | 1986-07-29 | 1988-11-23 | Miles Inc. | Human inter-alpha-trypsin inhibitor gene |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
WO1988003951A1 (en) | 1986-11-17 | 1988-06-02 | California Biotechnology, Inc. | Recombinant alzheimer's amyloid protein |
US5187153A (en) | 1986-11-17 | 1993-02-16 | Scios Nova Inc. | Methods of treatment using Alzheimer's amyloid polypeptide derivatives |
EP0285123A3 (en) | 1987-04-03 | 1989-02-01 | Stabra AG | A method for complete mutagenesis of nucleic acids |
IL87172A (en) | 1987-07-23 | 1994-12-29 | Univ Washington | Method of isolating highly purified tissue factor inhibitor |
US4966852A (en) | 1987-07-23 | 1990-10-30 | Monsanto Company | DNA clone of human tissue factor inhibitor |
US5106833A (en) | 1987-07-23 | 1992-04-21 | Washington University | Coagulation inhibitors |
GB2208511A (en) | 1987-08-07 | 1989-04-05 | Bayer Ag | Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology |
DK225488D0 (en) | 1988-04-26 | 1988-04-26 | Novo Industri As | POLYPEPTIDE |
IL87171A (en) | 1987-11-23 | 1995-08-31 | Monsanto Co | cDNA of human tissue factor inhibitor |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5663143A (en) | 1988-09-02 | 1997-09-02 | Dyax Corp. | Engineered human-derived kunitz domains that inhibit human neutrophil elastase |
US7078383B2 (en) | 1988-09-02 | 2006-07-18 | Dyax Corp. | ITI-D1 Kunitz domain mutants as HNE inhibitors |
ATE151110T1 (en) | 1988-09-02 | 1997-04-15 | Protein Eng Corp | PRODUCTION AND SELECTION OF RECOMBINANT PROTEINS WITH DIFFERENT BINDING SITES |
US5372933A (en) * | 1988-10-03 | 1994-12-13 | The Scripps Research Institute | Polypeptides that mimic receptor-induced binding sites, and methods of using same |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
ATE114332T1 (en) | 1989-05-13 | 1994-12-15 | Bayer Ag | PROTEINASE INHIBITORS, PROCESSES FOR THEIR PRODUCTION AND MEDICINES CONTAINING THEM. |
DK408089D0 (en) | 1989-08-18 | 1989-08-18 | Novo Nordisk As | PROTEINS |
US5378614A (en) | 1989-08-18 | 1995-01-03 | Novo Nordisk A/S | Vector and method for making tissue factor pathway inhibitor (TFPI) analogues in yeast |
US5278285A (en) | 1990-02-01 | 1994-01-11 | Bayer Aktiengesellschaft | Variant of Kunitz-type inhibitor derived from the α3-chain of human type VI collagen produced by recombinant DNA technology |
US5278144A (en) | 1990-09-04 | 1994-01-11 | Cor Therapeutics, Inc. | Antithrombosis agents |
US5583107A (en) | 1990-09-04 | 1996-12-10 | Cor Therapeutics, Inc. | Agents affecting thrombosis and hemostasis |
IL99585A0 (en) | 1990-10-01 | 1992-08-18 | Novo Nordisk As | Aprotinin analogues,their production and pharmaceutical compositions containing them |
EP0486001A1 (en) | 1990-11-13 | 1992-05-20 | Mochida Pharmaceutical Co., Ltd. | Recombinant urinary trypsin inhibitor fragments and drug composition |
US20030223977A1 (en) | 1991-03-01 | 2003-12-04 | Ley Arthur Charles | Kunitz domain mutants as cathepsin G inhibitors |
US5166133A (en) | 1991-04-17 | 1992-11-24 | Cetus Corporation | Method for inhibing adhesion of white blood cells to endothelial cells |
LU91067I2 (en) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab and its variants and immunochemical derivatives including immotoxins |
WO1993009233A2 (en) | 1991-10-31 | 1993-05-13 | The Salk Institute Biotechnology/Industrial Associates Inc. | Recombinant amyloid precursor protein inhibitor domain and treatment of various disease states |
IL104324A0 (en) | 1992-01-07 | 1993-05-13 | Novo Nordisk As | Variant of human kunitz-type protease inhibitor |
IL104325A (en) | 1992-01-07 | 2000-10-31 | Novo Nordisk As | Variants of human kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI) pharmaceutical compositions containing them a DNA construct encoding them their expression vectors a cell containing said DNA constructs and methods for the production of all the above |
IL104314A0 (en) | 1992-01-07 | 1993-05-13 | Novo Nordisk As | Human kunitz-type protease inhibitor and variants thereof,their production and pharmaceutical compositions containing them |
IL104326A0 (en) | 1992-01-07 | 1993-05-13 | Novo Nordisk As | Variant of human kunitz-type protease inhibitor |
IL104327A0 (en) | 1992-01-07 | 1993-05-13 | Novo Nordisk As | Variant of human kunitz-type protease inhibitor |
US5212091A (en) | 1992-03-02 | 1993-05-18 | Monsanto Company | Method of producing tissue factor pathway inhibitor |
US6063764A (en) | 1992-06-01 | 2000-05-16 | Washington University & Chiron Corp. | Method for using lipoprotein associated coagulation inhibitor to treat sepsis |
EP0651766A4 (en) * | 1992-07-13 | 1996-07-31 | Corvas Int Inc | BOVINE PANCREATIC TRYPSIN INHIBITOR DERIVED INHIBITORS OF FACTOR Xa. |
US5436153A (en) * | 1992-12-02 | 1995-07-25 | Sprecher; Cindy A. | Human amyloid protein precursor homolog and Kunitz-type inhibitor |
EP0740702A1 (en) | 1992-12-02 | 1996-11-06 | Zymogenetics, Inc. | Novel human amyloid protein precursor homologue and kunitz-type inhibitors |
US5426224A (en) | 1993-03-18 | 1995-06-20 | The University Of North Carolina At Chapel Hill | Mammalian DNA topoisomerase II inhibitor and method |
JP3929484B2 (en) * | 1993-09-14 | 2007-06-13 | ジェネンテック・インコーポレーテッド | Pharmaceutical composition comprising ecotin and its homologues |
US5455338A (en) | 1993-11-05 | 1995-10-03 | Zymogenetics, Inc. | DNA encoding novel human kunitz-type inhibitors and methods relating thereto |
US5951974A (en) | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
US5759548A (en) | 1993-11-30 | 1998-06-02 | Lxr Biotechnology Inc. | Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US5795865A (en) | 1994-01-11 | 1998-08-18 | Dyax Corp. | Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof |
US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
JP4137997B2 (en) * | 1994-01-11 | 2008-08-20 | ダイアックス コープ. | Inhibitors of human plasmin derived from the Kunitz domain |
US5795954A (en) | 1994-03-04 | 1998-08-18 | Genentech, Inc. | Factor VIIa inhibitors from Kunitz domain proteins |
US6008196A (en) | 1994-06-02 | 1999-12-28 | Hoechst Marion Roussel, Inc. | Perfluoroalkyl ketone inhibitors of elastase and processes for making the same |
AU707762B2 (en) | 1994-08-05 | 1999-07-22 | Novartis Vaccines And Diagnostics, Inc. | Production of tissue factor pathway inhibitor |
US5589359A (en) | 1994-08-05 | 1996-12-31 | Chiron Corporation | Chimeric proteins |
US5648331A (en) | 1994-08-26 | 1997-07-15 | G.D. Searle & Co. | Method of inhibiting tissue ischemia and reperfusion injury |
ATE346928T1 (en) * | 1994-10-18 | 2006-12-15 | Dendreon Corp | SERINE PROTEASE INHIBITORS AND COAGULATION-INHIBITING PROTEINS EXTRACTED FROM NEMATODES |
US6159938A (en) * | 1994-11-21 | 2000-12-12 | Cortech, Inc. | Serine protease inhibitors comprising α-keto heterocycles |
CN1160115C (en) * | 1994-12-12 | 2004-08-04 | 奥默罗斯公司 | Irrigation solution and method for inhibition of pain, inflammation |
JPH10510540A (en) * | 1994-12-12 | 1998-10-13 | オメロス メディカル システムズ,インコーポレーテッド | Irrigation solutions and methods for controlling pain, inflammation and convulsions |
US5914316A (en) | 1994-12-16 | 1999-06-22 | Washington University | Method of inhibiting intimal hyperplasia |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
ATE251141T1 (en) * | 1995-03-10 | 2003-10-15 | Berlex Lab | BENZAMIDINE DERIVATIVES, THEIR PRODUCTION AND THEIR USE AS ANTI-COAGULANTS |
US5695760A (en) | 1995-04-24 | 1997-12-09 | Boehringer Inglehiem Pharmaceuticals, Inc. | Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation |
US5804376A (en) | 1995-05-02 | 1998-09-08 | Incyte Pharmaceuticals, Inc. | Pancreas-derived serpin |
ZA963619B (en) * | 1995-05-08 | 1996-11-22 | Scios Inc | Protease inhibitor peptides |
AU5854096A (en) | 1995-05-08 | 1996-11-29 | Scios Inc. | Kunitz type protease inhibitors |
US5786328A (en) * | 1995-06-05 | 1998-07-28 | Genentech, Inc. | Use of kunitz type plasma kallikrein inhibitors |
US5780265A (en) * | 1995-06-05 | 1998-07-14 | Genentech, Inc. | Kunitz type plasma kallikrein inhibitors |
US6242414B1 (en) | 1995-06-07 | 2001-06-05 | Chiron Corporation | Regulation of cytokine synthesis and release |
US6126933A (en) | 1995-06-27 | 2000-10-03 | Genetics Institute | Methods of treating inflammatory bowel diseases by administering IL-11 |
US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
JPH0959838A (en) | 1995-08-24 | 1997-03-04 | Kuraray Co Ltd | Spun yarn |
JPH11512439A (en) | 1995-09-14 | 1999-10-26 | エルエックスアール バイオテクノロジー インコーポレイテッド | Composition having anti-apoptotic activity comprising a mixture of phospholipids |
US5853723A (en) | 1995-09-21 | 1998-12-29 | University Of Utah Research Foundation | Targeting of peg antibody conjugates to islet cells |
US5824870A (en) | 1995-11-06 | 1998-10-20 | Baszczynski; Chris | Commercial production of aprotinin in plants |
US5736364A (en) * | 1995-12-04 | 1998-04-07 | Genentech, Inc. | Factor viia inhibitors |
PT891426E (en) | 1996-03-11 | 2006-10-31 | Bayer Corp | HUMAN BICUNA |
US6013763A (en) * | 1996-06-04 | 2000-01-11 | Genentech, Inc. | Peptide variants of protein A |
JP3657700B2 (en) * | 1996-06-18 | 2005-06-08 | 新日本石油化学株式会社 | Method for producing high-quality nonwoven fabric |
US5869637A (en) | 1996-07-22 | 1999-02-09 | Incyte Pharmaceuticals, Inc. | Human Kallikrein |
US6214966B1 (en) | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
US6255455B1 (en) | 1996-10-11 | 2001-07-03 | The Trustees Of The University Of Pennsylvania | Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof |
US6258351B1 (en) | 1996-11-06 | 2001-07-10 | Shearwater Corporation | Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels |
US6262233B1 (en) | 1997-01-31 | 2001-07-17 | Human Genome Sciences, Inc. | Tissue factor pathway inhibitor-3 |
US5786238A (en) * | 1997-02-13 | 1998-07-28 | Generyal Dynamics Information Systems, Inc. | Laminated multilayer substrates |
US5962300A (en) | 1997-03-26 | 1999-10-05 | Incyte Pharmaceuticals, Inc. | Human kallikrein |
GB2339430A (en) | 1997-05-21 | 2000-01-26 | Biovation Ltd | Method for the production of non-immunogenic proteins |
US5990237A (en) | 1997-05-21 | 1999-11-23 | Shearwater Polymers, Inc. | Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines |
EP1027054A4 (en) | 1997-10-28 | 2002-11-04 | Vivus Inc | Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
AU755051B2 (en) | 1998-01-07 | 2002-12-05 | Debio Recherche Pharmaceutique S.A. | Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom |
AU2903899A (en) | 1998-03-12 | 1999-09-27 | Shearwater Polymers Inc. | Poly(ethylene glycol) derivatives with proximal reactive groups |
US6455639B1 (en) | 1998-03-24 | 2002-09-24 | Nof Corporation | Oxirane derivative and process for the preparation thereof |
US6017723A (en) | 1998-03-27 | 2000-01-25 | Long Island Jewish Medical Center | Method for isolating inhibitors of protease activity |
US6001596A (en) | 1998-05-07 | 1999-12-14 | Incyte Pharmaceuticals, Inc. | Growth-associated protease inhibitor heavy chain precursor |
US6087473A (en) * | 1999-05-26 | 2000-07-11 | Zymogenetics, Inc. | Kunitz domain polypeptide and materials and methods for making it |
JP2002517197A (en) * | 1998-06-03 | 2002-06-18 | サイオス,インコーポレーテッド | Protease inhibitor peptide |
ES2404074T3 (en) | 1998-08-06 | 2013-05-23 | Mountain View Pharmaceuticals, Inc. | Conjugates of urate peg oxidase and its use |
US6783965B1 (en) | 2000-02-10 | 2004-08-31 | Mountain View Pharmaceuticals, Inc. | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
JP2002524076A (en) | 1998-09-03 | 2002-08-06 | ザイモジェネティクス,インコーポレイティド | Kunitz domain polypeptide ZKUN6 |
US7067144B2 (en) | 1998-10-20 | 2006-06-27 | Omeros Corporation | Compositions and methods for systemic inhibition of cartilage degradation |
US6565874B1 (en) | 1998-10-28 | 2003-05-20 | Atrix Laboratories | Polymeric delivery formulations of leuprolide with improved efficacy |
AU2346900A (en) | 1998-11-30 | 2000-06-19 | Eli Lilly And Company | Erythropoietic compounds |
JP2002534959A (en) | 1998-12-08 | 2002-10-22 | バイオベーション リミテッド | Methods for modifying immunogenic proteins |
US20030012969A1 (en) | 1999-04-06 | 2003-01-16 | Clark Bert Thomas | Soluble membrane strengthened paper products |
DE60024809D1 (en) | 1999-04-29 | 2006-01-19 | Novo Nordisk As | USE OF ANTI-HBP ANTIBODY INHIBITING THE RELEASE OF BRADYKININE |
US6605316B1 (en) | 1999-07-31 | 2003-08-12 | The Regents Of The University Of California | Structures and fabrication techniques for solid state electrochemical devices |
US6180607B1 (en) | 1999-08-05 | 2001-01-30 | Christopher Davies | Protein having proteinase inhibitor activity |
CA2589418A1 (en) | 1999-08-24 | 2001-03-01 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
JP2003513681A (en) | 1999-11-12 | 2003-04-15 | マキシゲン・ホールディングス・リミテッド | Interferon gamma conjugate |
US6348558B1 (en) | 1999-12-10 | 2002-02-19 | Shearwater Corporation | Hydrolytically degradable polymers and hydrogels made therefrom |
US6544760B2 (en) | 1999-12-22 | 2003-04-08 | Zymogenetics, Inc. | Kunitz domain polypeptide Zkun11 |
EP2070968A3 (en) | 1999-12-22 | 2013-07-24 | Nektar Therapeutics | Method for the Preparation of 1-Benzotriazolyl Carbonate Esters of Poly(ethylene glycol) |
US6413507B1 (en) | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
US20020102703A1 (en) | 1999-12-29 | 2002-08-01 | Sheppard Paul O. | Kunitz domain polypeptide zkun10 |
GB9930882D0 (en) * | 1999-12-30 | 2000-02-23 | Nps Allelix Corp | GLP-2 formulations |
WO2001068707A1 (en) | 2000-03-13 | 2001-09-20 | Eli Lilly And Company | Human hepatocyte growth factor activator inhibitor homologue |
CA2747325A1 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
CN1331213A (en) | 2000-06-30 | 2002-01-16 | 上海博德基因开发有限公司 | Polypeptide-human macroprotein 10.01 and pllynucleotide for coding it |
DE10034357C1 (en) | 2000-07-14 | 2001-12-13 | Elotherm Gmbh | Apparatus, for hardening the surfaces which limit a recess between two teeth of a toothed wheel or a toothed rack, comprises an inductor for heating each surface, a quenching device |
MXPA03002049A (en) | 2000-09-08 | 2003-07-24 | Schering Corp | Mammalian genes; related reagents and methods. |
AU2002217014B2 (en) | 2000-10-31 | 2006-11-02 | Debiopharm S.A. | Suspension of an EPI-hNE protein, process of preparation thereof, dry powder aerosol derived therefrom, pharmaceutical compositions containing said suspension or aerosol, and their uses |
US20030113726A1 (en) | 2000-12-04 | 2003-06-19 | Zenta Tsuchihashi | Human single nucleotide polymorphisms |
TW593427B (en) | 2000-12-18 | 2004-06-21 | Nektar Therapeutics Al Corp | Synthesis of high molecular weight non-peptidic polymer derivatives |
JP2004531550A (en) | 2001-05-11 | 2004-10-14 | アラダイム コーポレーション | Methods and formulations for optimizing molecular properties of proteins delivered by inhalation |
EA007408B1 (en) | 2001-05-21 | 2006-10-27 | Нектар Терапьютикс | Pulmonary administration of chemically modified insulin |
US20040152633A1 (en) | 2001-05-31 | 2004-08-05 | Jorgensen Marianne Ulrich | Kunitz-type sequences and polypeptides |
WO2003033009A2 (en) | 2001-07-10 | 2003-04-24 | Omnio Ab | Novel drug targets for arthritis |
US6926250B1 (en) | 2001-07-10 | 2005-08-09 | Sankyo Seiki Mfg. Co., Ltd. | Valve driving device |
US20050222023A1 (en) | 2002-02-07 | 2005-10-06 | Hans-Peter Hauser | Albumin-fused kunitz domain peptides |
CN101166762A (en) | 2002-02-07 | 2008-04-23 | 达尔塔生物技术有限公司 | Albumin-fused Kunitz domain peptides |
AU2003231865A1 (en) | 2002-05-31 | 2003-12-19 | Genzyme Corporation | Alpha acyloxyacetamides for kallikrein and urokinase inhibition |
EP2311432B1 (en) * | 2002-06-07 | 2014-12-24 | Dyax Corporation | Modified kunitz domain polypeptides and their use for reducing ischemia or the onset of a systemic inflammatory response associated with a surgical procedure |
US7153829B2 (en) * | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
PL375254A1 (en) | 2002-07-24 | 2005-11-28 | F.Hoffmann-La Roche Ag | Pegylated t20 polypeptide |
EP1526872A1 (en) | 2002-07-24 | 2005-05-04 | F. Hoffmann-La Roche Ag | Polyalkylene glycol acid additives |
DK1542710T3 (en) | 2002-08-28 | 2012-10-15 | Dyax Corp | Method of preserving organs and tissues |
US8129330B2 (en) | 2002-09-30 | 2012-03-06 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
US20040062748A1 (en) | 2002-09-30 | 2004-04-01 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
US7314613B2 (en) | 2002-11-18 | 2008-01-01 | Maxygen, Inc. | Interferon-alpha polypeptides and conjugates |
US9125880B2 (en) | 2002-12-26 | 2015-09-08 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of interferon-beta with enhanced biological potency |
EP1587907B1 (en) | 2003-01-07 | 2011-03-02 | Dyax Corporation | Kunitz domain library |
US20040180827A1 (en) | 2003-01-08 | 2004-09-16 | Chiron Corporation | Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants |
SI1599222T1 (en) | 2003-01-08 | 2009-08-31 | Novartis Vaccines & Diagnostic | Stabilized aqueous compositions comprising tissue factor pathway inhibitor (tfpi) or tissue factor pathway inhibitor variant |
DE10301300B4 (en) | 2003-01-15 | 2009-07-16 | Curacyte Chemistry Gmbh | Use of acylated 4-amidino- and 4-guanidinobenzylamines for the inhibition of plasma kallikrein |
US6989369B2 (en) * | 2003-02-07 | 2006-01-24 | Dyax Corp. | Kunitz domain peptides |
CA2531062A1 (en) | 2003-07-02 | 2005-01-13 | Emory University | Compositions and methods for use of a protease inhibitor and adenosine for preventing organ ischemia and reperfusion injury |
AU2004266246A1 (en) | 2003-08-14 | 2005-03-03 | Dyax Corp. | Endotheliase-2 ligands |
JP4739207B2 (en) | 2003-08-29 | 2011-08-03 | ダイアックス コーポレーション | PolyPEGylated protease inhibitors |
EP1663279A4 (en) | 2003-08-29 | 2009-02-18 | Dyax Corp | Modified protease inhibitors |
WO2005027753A1 (en) | 2003-09-19 | 2005-03-31 | St. Jude Medical, Inc. | Apparatus and methods for tissue gathering and securing |
JP2007507538A (en) | 2003-10-02 | 2007-03-29 | エラン ファーマシューティカルズ,インコーポレイテッド | Pain relief method |
US20060228331A1 (en) | 2003-10-10 | 2006-10-12 | Novo Nordisk A/S | IL-21 Derivatives and variants |
WO2005041631A2 (en) | 2003-10-21 | 2005-05-12 | Dyax Corp. | Endotheliase-1 ligands |
WO2005075665A2 (en) | 2004-02-03 | 2005-08-18 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with plasma kallikrein (klkb1) |
JP4775259B2 (en) | 2004-03-31 | 2011-09-21 | 味の素株式会社 | Aniline derivative |
EP1807451A2 (en) | 2004-08-03 | 2007-07-18 | Dyax Corporation | Hk1-binding proteins |
US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
US20060111296A1 (en) | 2004-11-22 | 2006-05-25 | Dyax Corp. | Plasmin-inhibitory therapies |
ITMI20042442A1 (en) | 2004-12-21 | 2005-03-21 | Aliveris S R L | FOOD PASTA WITH IMPROVED DIGESTIBILITY CHARACTERISTICS |
RU2514878C2 (en) | 2004-12-23 | 2014-05-10 | Ксл Бехринг Гмбх | Prevention of formation and/or stabilisation of thrombi |
WO2006089005A2 (en) | 2005-02-17 | 2006-08-24 | Bristol-Myers Squibb Company | Combination of selective factor viia and/or xia and plasma kallikrein inhibitors |
EP2500031A3 (en) | 2005-02-24 | 2012-12-26 | Joslin Diabetes Center, Inc. | Compositions and Methods for Treating Vascular Permeability |
SI1877435T2 (en) | 2005-05-04 | 2021-05-31 | Zealand Pharma A/S | Glucagon-like-peptide-2 (glp-2) analogues |
US20070079096A1 (en) | 2005-09-30 | 2007-04-05 | Chih-Wei Chen | Data storage unit access authorization table automatic rebuilding method and system |
CA2561626C (en) | 2005-09-30 | 2013-11-26 | 9141-0720 Quebec Inc. | Motorized closure operating device with electronic control system |
PT1981519T (en) | 2005-12-29 | 2018-02-23 | Dyax Corp | Protease inhibition |
US7276480B1 (en) * | 2005-12-30 | 2007-10-02 | Dyax Corp. | Prevention and reduction of blood loss |
JP2009529542A (en) | 2006-03-10 | 2009-08-20 | ダイアックス コーポレーション | Ecarantide formulation |
ES2682646T3 (en) | 2006-03-16 | 2018-09-21 | Dyax Corp. | Compositions and methods for the treatment of ophthalmic disorders |
US20080031426A1 (en) | 2006-06-27 | 2008-02-07 | Weeks Walter L | Audio, video, and navigational law enforcement system and method |
EP1873344A1 (en) | 2006-06-30 | 2008-01-02 | Sika Technology AG | Silicone sealed bonding |
CA2658523C (en) | 2006-07-31 | 2012-06-12 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
WO2008060764A2 (en) | 2006-10-05 | 2008-05-22 | Drugtech Corporation | Topical therapies for oral mucositis and other conditions |
EP2195010A4 (en) | 2007-08-21 | 2012-03-14 | Genzyme Corp | Treatment with kallikrein inhibitors |
JP2010536883A (en) | 2007-08-23 | 2010-12-02 | ジェンザイム・コーポレーション | Treatment with kallikrein inhibitors |
EP2245153A4 (en) | 2008-02-13 | 2011-06-22 | Dyax Corp | Improved methods for producing specific binding pairs |
DE102008027574A1 (en) | 2008-06-10 | 2009-12-17 | Merck Patent Gmbh | New pyrrolidine derivatives as MetAP-2 inhibitors |
DE102008033095A1 (en) | 2008-07-15 | 2010-01-28 | Uhde Gmbh | Apparatus for slag removal from a coal gasification reactor |
CA2744235A1 (en) | 2009-01-06 | 2010-07-15 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
EP2521568B1 (en) | 2010-01-06 | 2018-07-25 | Dyax Corp. | Plasma kallikrein binding proteins |
IL310186A (en) | 2011-01-06 | 2024-03-01 | Takeda Pharmaceuticals Co | Plasma kallikrein binding proteins |
WO2012142308A1 (en) | 2011-04-13 | 2012-10-18 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
ES2718347T3 (en) | 2013-01-20 | 2019-07-01 | Dyax Corp | Evaluation, trials and treatment of disorders mediated by pKal |
AU2015235967B2 (en) | 2014-03-27 | 2020-10-22 | Takeda Pharmaceutical Company Limited | Compositions and methods for treatment of diabetic macular edema |
-
2003
- 2003-06-06 EP EP10180484.7A patent/EP2311432B1/en not_active Expired - Lifetime
- 2003-06-06 US US10/456,986 patent/US7064107B2/en not_active Expired - Lifetime
- 2003-06-06 CA CA2488558A patent/CA2488558C/en not_active Expired - Lifetime
- 2003-06-06 ES ES10180486.2T patent/ES2559927T3/en not_active Expired - Lifetime
- 2003-06-06 PT PT101804847T patent/PT2311432E/en unknown
- 2003-06-06 DK DK07023364.8T patent/DK1941867T3/en active
- 2003-06-06 PT PT07023364T patent/PT1941867E/en unknown
- 2003-06-06 DK DK10180486.2T patent/DK2298278T3/en active
- 2003-06-06 EP EP07023364A patent/EP1941867B1/en not_active Expired - Lifetime
- 2003-06-06 AT AT03757339T patent/ATE477020T1/en active
- 2003-06-06 EP EP03757339A patent/EP1531791B1/en not_active Expired - Lifetime
- 2003-06-06 DE DE60333758T patent/DE60333758D1/en not_active Expired - Lifetime
- 2003-06-06 ES ES03757339T patent/ES2348230T3/en not_active Expired - Lifetime
- 2003-06-06 AT AT07023364T patent/ATE528014T1/en active
- 2003-06-06 DK DK03757339.1T patent/DK1531791T3/en active
- 2003-06-06 EP EP10180486.2A patent/EP2298278B1/en not_active Expired - Lifetime
- 2003-06-06 ES ES07023364T patent/ES2372978T3/en not_active Expired - Lifetime
- 2003-06-06 AU AU2003243394A patent/AU2003243394B2/en not_active Expired
- 2003-06-06 PT PT03757339T patent/PT1531791E/en unknown
- 2003-06-06 ES ES10180484.7T patent/ES2528254T3/en not_active Expired - Lifetime
- 2003-06-06 DK DK10180484.7T patent/DK2311432T3/en active
- 2003-06-06 PT PT101804862T patent/PT2298278E/en unknown
- 2003-06-06 WO PCT/US2003/017665 patent/WO2003103475A2/en active Search and Examination
- 2003-06-06 JP JP2004510605A patent/JP2005534647A/en active Pending
-
2005
- 2005-12-30 US US11/322,960 patent/US20060194727A1/en not_active Abandoned
-
2007
- 2007-04-27 US US11/796,272 patent/US20080064637A1/en not_active Abandoned
- 2007-10-30 US US11/929,729 patent/US8124586B2/en active Active
- 2007-10-30 US US11/930,018 patent/US20080131426A1/en not_active Abandoned
- 2007-10-30 US US11/930,012 patent/US7811991B2/en not_active Expired - Lifetime
- 2007-10-31 US US11/931,373 patent/US7851442B2/en not_active Expired - Lifetime
- 2007-10-31 US US11/931,635 patent/US20080152656A1/en not_active Abandoned
- 2007-11-02 US US11/934,181 patent/US20080260752A1/en not_active Abandoned
-
2008
- 2008-05-29 AU AU2008202377A patent/AU2008202377B2/en not_active Expired
- 2008-12-31 HK HK08114131.3A patent/HK1119955A1/en not_active IP Right Cessation
- 2008-12-31 HK HK11108085.6A patent/HK1154211A1/en not_active IP Right Cessation
- 2008-12-31 HK HK11108870.5A patent/HK1154513A1/en not_active IP Right Cessation
-
2010
- 2010-01-12 JP JP2010004265A patent/JP5249251B2/en not_active Expired - Lifetime
- 2010-11-22 US US12/951,543 patent/US8710007B2/en active Active
-
2011
- 2011-04-20 AU AU2011201811A patent/AU2011201811A1/en not_active Abandoned
-
2012
- 2012-01-11 CY CY20121100027T patent/CY1112228T1/en unknown
- 2012-11-01 JP JP2012242083A patent/JP2013049698A/en active Pending
-
2014
- 2014-04-28 US US14/263,764 patent/US9480733B2/en not_active Expired - Lifetime
-
2016
- 2016-06-07 US US15/175,644 patent/US10245307B2/en not_active Expired - Lifetime
-
2019
- 2019-02-21 US US16/281,276 patent/US11344610B2/en not_active Expired - Lifetime
Non-Patent Citations (1)
Title |
---|
SILVERBERG, M. ET AL.: "Blood: Principles and Practice of Hematology", 1995, JB LIPPINCOTT CO., article "The Contact System and Its Disorders" |
Cited By (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8663629B2 (en) | 1994-01-11 | 2014-03-04 | Dyax Corp. | Kallikrein-binding “kunitz domain” proteins and analogues thereof |
US9114144B2 (en) | 2002-06-07 | 2015-08-25 | Dyax Corp. | Kallikrein-inhibitor therapies |
US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
US10245307B2 (en) | 2002-06-07 | 2019-04-02 | Dyax Corp. | Prevention and reduction of blood loss |
US9480733B2 (en) | 2002-06-07 | 2016-11-01 | Dyax Corp. | Prevention and reduction of blood loss |
US8124586B2 (en) | 2002-06-07 | 2012-02-28 | Dyax Corp. | Prevention and reduction of blood loss |
US11344610B2 (en) | 2002-06-07 | 2022-05-31 | Takeda Pharmaceutical Company Limited | Prevention and reduction of blood loss |
US7704949B2 (en) | 2002-06-07 | 2010-04-27 | Dyax Corp. | Kallikrein-inhibitor therapies |
US8034775B2 (en) | 2002-06-07 | 2011-10-11 | Dyax Corp. | Kallikrein-inhibitor therapies |
US7811991B2 (en) | 2002-06-07 | 2010-10-12 | Dyax Corp. | Prevention and reduction of blood loss |
US7851442B2 (en) | 2002-06-07 | 2010-12-14 | Dyax Corp. | Prevention and reduction of blood loss |
EP1542710A4 (en) * | 2002-08-28 | 2007-11-28 | Dyax Corp | Methods for preserving organs and tissues |
EP1542710A1 (en) * | 2002-08-28 | 2005-06-22 | Dyax Corp. | Methods for preserving organs and tissues |
US7718617B2 (en) | 2002-08-28 | 2010-05-18 | Dyax Corp. | Methods for preserving organs and tissues |
AU2003243413B2 (en) * | 2002-08-28 | 2009-07-09 | Takeda Pharmaceutical Company Limited | Methods for preserving organs and tissues |
EP2386310A3 (en) * | 2002-08-28 | 2012-06-13 | Dyax Corp. | Methods for preserving organs and tissues |
EP1812049A4 (en) * | 2004-09-27 | 2012-12-26 | Dyax Corp | Kallikrein inhibitors and uses thereof |
EP3202414A1 (en) * | 2004-09-27 | 2017-08-09 | Dyax Corp. | Kallikrein inhibitors and uses thereof |
US8188045B2 (en) | 2004-09-27 | 2012-05-29 | Dyax Corp. | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
JP2008514624A (en) * | 2004-09-27 | 2008-05-08 | ダイアックス コーポレーション | Kallikrein inhibitors and uses thereof |
US9757437B2 (en) | 2004-09-27 | 2017-09-12 | Dyax Corp. | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
JP2013166791A (en) * | 2004-09-27 | 2013-08-29 | Dyax Corp | Kallikrein inhibitor and use of the same |
EP2674164A1 (en) * | 2004-09-27 | 2013-12-18 | Dyax Corporation | Kallikrein inhibitors and uses thereof |
EP1812049A2 (en) * | 2004-09-27 | 2007-08-01 | Dyax Corporation | Kallikrein inhibitors and uses thereof |
JP2011213738A (en) * | 2004-09-27 | 2011-10-27 | Dyax Corp | Kallikrein inhibitor and use thereof |
US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
US8715672B2 (en) | 2004-12-23 | 2014-05-06 | Csl Behring Gmbh | Treatment of diseases linked to pathological kinin formation |
US8119137B2 (en) * | 2004-12-23 | 2012-02-21 | Csl Behring Gmbh | Prevention of thrombus formation and/or stabilization with inhibitors of factor XII or activated factor XII |
US9107928B2 (en) | 2006-03-16 | 2015-08-18 | Dyax Corp. | Compositions and methods for treating ophthalmic disorders |
EP2374472A3 (en) * | 2006-03-16 | 2012-05-16 | Dyax Corp. | Compositions and methods for treating ophthalmic disorders |
US8637454B2 (en) | 2009-01-06 | 2014-01-28 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
EP4011917A1 (en) | 2010-01-06 | 2022-06-15 | Takeda Pharmaceutical Company Limited | Plasma kallikrein binding proteins |
WO2011085103A2 (en) | 2010-01-06 | 2011-07-14 | Dyax Corp. | Plasma kallikrein binding proteins |
US8822653B2 (en) | 2010-01-06 | 2014-09-02 | Dyax Corp. | Plasma kallikrein binding proteins |
US10336832B2 (en) | 2010-01-06 | 2019-07-02 | Dyax Corp. | Methods of inhibiting plasma kallikrein in edema patient |
US11505620B2 (en) | 2010-01-06 | 2022-11-22 | Takeda Pharmaceutical Company Limited | Methods of detecting plasma kallikrein |
EP3459564A1 (en) | 2010-01-06 | 2019-03-27 | Dyax Corp. | Plasma kallikrein binding proteins |
WO2011089022A1 (en) | 2010-01-25 | 2011-07-28 | Ecp Entwicklungsgesellschaft Mbh | Fluid pump having a radially compressible rotor |
US9266964B2 (en) | 2011-01-06 | 2016-02-23 | Dyax Corp. | Method of treating hereditary angioedema using plasma kallikrein binding antibodies |
US11401346B2 (en) | 2011-01-06 | 2022-08-02 | Takeda Pharmaceutical Company Limited | Nucleic acids encoding plasma kallikrein binding proteins |
US10370453B2 (en) | 2011-01-06 | 2019-08-06 | Dyax Corp. | Plasma kallikrein binding proteins |
US8816055B2 (en) | 2011-01-06 | 2014-08-26 | Dyax Corp. | Plasma kallikrein binding proteins |
AU2012267546B2 (en) * | 2011-06-10 | 2015-12-24 | Ionis Pharmaceuticals, Inc. | Methods for modulating kallikrein (KLKB1) expression |
US9315811B2 (en) | 2011-06-10 | 2016-04-19 | Ionis Pharmaceuticals, Inc. | Methods for modulating kallikrein (KLKB1) expression |
US9322021B2 (en) | 2011-06-29 | 2016-04-26 | Ionis Pharmaceuticals, Inc. | Methods for modulating kallikrein (KLKB1) expression |
EP3456744A1 (en) | 2013-01-20 | 2019-03-20 | Dyax Corp. | Evaluation and treatment of bradykinin-mediated disorders |
EP3470837A1 (en) | 2013-01-20 | 2019-04-17 | Dyax Corp. | Treatment of pkal-mediated disorders |
EP4234583A2 (en) | 2013-01-20 | 2023-08-30 | Takeda Pharmaceutical Company Limited | Evaluation and treatment of bradykinin-mediated disorders |
WO2014113712A1 (en) | 2013-01-20 | 2014-07-24 | Dyax Corp. | Evaluation and treatment of bradykinin-mediated disorders |
US11840686B2 (en) | 2013-08-28 | 2023-12-12 | Ionis Pharmaceuticals, Inc. | Modulation of prekallikrein (PKK) expression |
US9670492B2 (en) | 2013-08-28 | 2017-06-06 | Ionis Pharmaceuticals, Inc. | Modulation of prekallikrein (PKK) expression |
US11053500B2 (en) | 2013-08-28 | 2021-07-06 | lonis Pharmaceuticals, Inc. | Modulation of prekallikrein (PKK) expression |
WO2015061182A1 (en) | 2013-10-21 | 2015-04-30 | Dyax Corp. | Diagnosis and treatment of autoimmune diseases |
EP3808857A1 (en) | 2013-10-21 | 2021-04-21 | Dyax Corp. | Assays for determining plasma kallikrein system biomarkers |
EP3913364A1 (en) | 2013-10-21 | 2021-11-24 | Dyax Corp. | Diagnosis and treatment of autoimmune diseases |
EP3848057A1 (en) | 2014-01-21 | 2021-07-14 | Dyax Corp. | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema |
WO2015112578A1 (en) | 2014-01-21 | 2015-07-30 | Dyax Corp. | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema |
US11046785B2 (en) | 2014-03-27 | 2021-06-29 | Takeda Pharmaceutical Company Limited | Compositions and methods for treatment of diabetic macular edema |
US10428158B2 (en) | 2014-03-27 | 2019-10-01 | Dyax Corp. | Compositions and methods for treatment of diabetic macular edema |
US11613752B2 (en) | 2014-05-01 | 2023-03-28 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating PKK expression |
US10294477B2 (en) | 2014-05-01 | 2019-05-21 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating PKK expression |
EP3916020A1 (en) | 2015-03-30 | 2021-12-01 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack |
US11286307B2 (en) | 2015-12-11 | 2022-03-29 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
WO2017100679A1 (en) | 2015-12-11 | 2017-06-15 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
WO2020047352A1 (en) | 2018-08-30 | 2020-03-05 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
WO2020186132A1 (en) | 2019-03-14 | 2020-09-17 | Dyax Corp. | Treating hereditary angioedema attack with reduced dosage of antibodies binding to human plasma kallikrein |
WO2021146160A1 (en) | 2020-01-13 | 2021-07-22 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack |
WO2021202948A2 (en) | 2020-04-04 | 2021-10-07 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for treating acute respiratory distress syndrome |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11344610B2 (en) | Prevention and reduction of blood loss | |
US7276480B1 (en) | Prevention and reduction of blood loss | |
AU2013205029A1 (en) | Prevention and reduction of blood loss |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003243394 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2488558 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004510605 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003757339 Country of ref document: EP |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWP | Wipo information: published in national office |
Ref document number: 2003757339 Country of ref document: EP |